Key Record Dates
ClinicalTrials.gov Identifier: | NCT05660967 |
---|---|
Brief Title: | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3) |
First Submitted : | November 29, 2022 |
First Submitted that Met QC Criteria : | December 14, 2022 |
First Posted : | December 21, 2022 |
Last Update Submitted that Met QC Criteria : | April 2, 2024 |
Last Update Posted : | April 3, 2024 |